The New England journal of medicine
-
Comment Letter
Bezlotoxumab and Recurrent Clostridium difficile Infection.
-
Randomized Controlled Trial Multicenter Study
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
In a previous study, a single injection of inclisiran, a chemically synthesized small interfering RNA designed to target PCSK9 messenger RNA, was found to produce sustained reductions in low-density lipoprotein (LDL) cholesterol levels over the course of 84 days in healthy volunteers. ⋯ In our trial, inclisiran was found to lower PCSK9 and LDL cholesterol levels among patients at high cardiovascular risk who had elevated LDL cholesterol levels. (Funded by the Medicines Company; ORION-1 ClinicalTrials.gov number, NCT02597127 .).
-
Historical Article
Yellow Fever - Once Again on the Radar Screen in the Americas.